TEM (Tempus AI, Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TEM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | David R Epstein | Director | Sell | — | — |
| 2026-09-03 | Jennifer A Doudna | Director | Sell | — | — |
| 2026-09-03 | Ryan Fukushima | CEO, Data | Sell | — | — |
| 2026-09-01 | Nadja West | Director | Sell | — | — |
| 2026-08-27 | ERIC P LEFKOFSKY | CEO and Chairman | Sell | — | — |
| 2026-08-27 | ERIC P LEFKOFSKY | CEO and Chairman | Sell | — | — |
| 2026-08-25 | Thomas Edward Schoenherr | CEO, Diagnostics | Sell | — | — |
| 2026-08-25 | Ryan Fukushima | CEO, Data | Sell | — | — |
| 2026-08-20 | Ryan M Bartolucci | Chief Accounting Officer | Sell | — | — |
| 2026-08-20 | Andrew Polovin | EVP, Chief Legal Officer | Sell | — | — |
| 2026-08-20 | Ryan Fukushima | CEO, Data | Sell | — | — |
| 2026-08-20 | Thomas Edward Schoenherr | CEO, Diagnostics | Sell | — | — |
| 2026-08-20 | ERIC P LEFKOFSKY | CEO and Chairman | Sell | — | — |
| 2026-08-20 | James William Rogers | Chief Financial Officer | Sell | — | — |
| 2026-08-18 | Nadja West | Director | Sell | — | — |
| 2026-08-14 | Ryan Fukushima | CEO, Data | G | — | — |
| 2026-08-11 | Ryan Fukushima | CEO, Data | Sell | — | — |
| 2026-08-05 | David R Epstein | Director | Sell | — | — |
| 2026-08-05 | Ryan Fukushima | CEO, Data | Sell | — | — |
| 2026-07-31 | James William Rogers | Chief Financial Officer | A | — | — |
| 2026-07-31 | Andrew Polovin | EVP, Chief Legal Officer | A | — | — |
| 2026-07-30 | ERIC P LEFKOFSKY | CEO and Chairman | Sell | — | — |
| 2026-07-10 | Ryan Fukushima | CEO, Data | Sell | — | — |
| 2026-07-08 | Ryan Fukushima | CEO, Data | Sell | — | — |
| 2026-07-01 | ERIC P LEFKOFSKY | CEO and Chairman | Sell | — | — |
| 2026-06-29 | James William Rogers | Chief Financial Officer | Sell | — | — |
| 2026-06-29 | Jennifer A Doudna | Director | Sell | — | — |
| 2026-06-03 | David R Epstein | Director | Sell | — | — |
| 2026-05-29 | ERIC P LEFKOFSKY | CEO and Chairman | Sell | — | — |
| 2026-05-26 | PETER J BARRIS | Director | A | — | — |
| 2026-05-26 | Jennifer A Doudna | Director | A | — | — |
| 2026-05-26 | David R Epstein | Director | A | — | — |
| 2026-05-26 | Wayne A.I. Frederick | Director | A | — | — |
| 2026-05-26 | Scott Gottlieb | Director | A | — | — |
| 2026-05-26 | Theodore Leonsis | Director | A | — | — |
| 2026-05-26 | Nadja West | Director | A | — | — |
| 2026-05-26 | Eric D Belcher | Director | A | — | — |
| 2026-05-21 | Ryan M Bartolucci | Chief Accounting Officer | Sell | — | — |
| 2026-05-21 | Ryan Fukushima | CEO, Data | Sell | — | — |
| 2026-05-21 | ERIC P LEFKOFSKY | CEO and Chairman | Sell | — | — |
| 2026-05-21 | Andrew Polovin | EVP, Chief Legal Officer | Sell | — | — |
| 2026-05-21 | James William Rogers | Chief Financial Officer | Sell | — | — |
| 2026-05-21 | Thomas Edward Schoenherr | CEO, Diagnostics | Sell | — | — |
| 2026-05-15 | Ryan Fukushima | CEO, Data | G | — | — |
| 2026-05-06 | Ryan Fukushima | CEO, Data | A | — | — |
| 2026-05-06 | Ryan M Bartolucci | Chief Accounting Officer | A | — | — |
| 2026-05-06 | Andrew Polovin | EVP, Chief Legal Officer | A | — | — |
| 2026-05-06 | James William Rogers | Chief Financial Officer | A | — | — |
| 2026-05-06 | Thomas Edward Schoenherr | CEO, Diagnostics | A | — | — |
| 2026-04-30 | ERIC P LEFKOFSKY | CEO and Chairman | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 31,385,066 | — |
| — | 10%+ Owner | 16,560,249 | — |
| — | 10%+ Owner | 16,002,638 | — |
| — | 10%+ Owner | 15,360,249 | — |
| — | CEO and Chairman | 2,915,261 | — |
| — | CEO, Data | 609,883 | — |
| — | EVP, Chief Legal Officer | 146,067 | — |
| — | Chief Financial Officer | 132,337 | — |
| — | Director | 121,424 | — |
| — | Director | 88,180 | — |
| — | CEO, Diagnostics | 87,021 | — |
| — | EVP, Chief Admin. Officer | 85,466 | — |
| — | Chief Accounting Officer | 67,866 | — |
| — | Director | 40,749 | — |
| — | Director | 35,457 | — |
| — | Director | 31,981 | — |
| — | Director | 31,094 | — |
| — | Director | 30,749 | — |
| — | Director | 25,942 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TEM quote page; the site-wide leaderboard is on the insider transactions hub.